Navigation Links
Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger
Date:12/4/2008

." Such statements include, but are not limited to, statements regarding the proposed transaction, including the timing for closing, the completion of MMR's audited financial statements, the benefits to Favrille's stakeholders, the benefits provided by MMR's products, including cost reductions, improved care and reduced medical errors, proposed reforms to the U.S. healthcare system, MMR's initiatives and the prices for its products following the merger and Favrille's ability to settle creditor claims. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, the risk that Favrille and MMR may not be able to complete the proposed transaction in a timely manner or at all, the risk MMR's products are not adopted or viewed favorably by the healthcare community, risks related to the current uncertainty and instability in financial and lending markets, risks related to the listing status of Favrille's common stock on the OTC Bulletin Boards, risks relating to Favrille's ability to negotiate settlements with its creditors, risks relating to the ability of Favrille and MMR to satisfy conditions to closing the proposed merger transaction and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. The combined company will also be subject to a number of risks and uncertainties, including risks relating to the need to have access to additional capital to finance the business until it can generate sufficient cash flow from operations and risks relating to the adoption of personal health care records and the development of a viable revenue generating business model. All forward-looking statements are qualified in their entirety by this cautionary statement. Favr
'/>"/>
SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction
2. Favrille Announces Receipt of Nasdaq Letters
3. Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
4. Favrille Announces Workforce Reduction
5. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
6. Favrille Reports First Quarter 2008 Financial Results
7. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. Favrille Announces $21.1 Million Registered Direct Offering
10. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
11. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... of Compensatory Award Will Now Proceed -, MADISON, N.J., ... its motion for judgment as a matter of law on ... Scroggin v.,Wyeth, in the U.S. District Court, Eastern District of ... punitive damages award of,$19,360,000 rendered by the Little Rock jury ...
... USA Study to Evaluate Treatment of Coronary Artery Disease ... Patients in Real-World Setting, ... of the XIENCE V(TM) USA post-approval study, with six,hospital centers already ... Drug Administration approved the XIENCE V(TM),Everolimus Eluting Coronary Stent System. The ...
... 10 most promising drugs ... TSX Exchange Symbol: ... the "Company") (TSX:RVX) novel lead ApoA-I drug,candidate, RVX-208 has been ... (CVD) drugs available for strategic partnering by an,independent committee assembled ...
Cached Biology Technology:Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 2Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 2Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 4Industry Leaders Select Resverlogix's RVX-208 2Industry Leaders Select Resverlogix's RVX-208 3
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... bird flu virus H5N1 emerged in late 2005 and replaced ... southern China, despite an ongoing program to vaccinate poultry, according ... with scientists at St. Jude Children's Research Hospital. , The ... the increased occurrence of H5N1 poultry infections since October 2005, ...
... first large-scale analysis of proteins in the brains of ... and mechanisms that may one day lead to new ... in the current issue of Molecular Psychiatry, released on-line ... and point to profound changes in brain function related ...
... immune response to the 1918 influenza virus provides new ... in an article appearing online today in the journal ... 1918 virus triggers a hyperactive immune response that may ... their results suggest that it is the combination of ...
Cached Biology News:Control measures fail to stop spread of new H5N1 virus 2High-tech research shows cocaine changes proteins and brain function 2Mouse study reveals new clues about virulence of 1918 influenza virus 2Mouse study reveals new clues about virulence of 1918 influenza virus 3
... EA. Ultrospec 6300 pro UV/Visible ... the Pharmacopoeia in terms of instrument specification ... being able to be used for rapid, ... excellent scanning capability., *Press to read high ...
... Cy3 Ab Labeling Kit, 1 kit. ... with CyDye fluorescent dyes. Conjugations are ... complete within 1 h. Dyes are ... to ensure consistent labelings. Category: Blotting ...
nucleophosmin (nucleolar phosphoprotein B23, numatrin), mRNA...
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
Biology Products: